Halozyme Therapeutics (HALO) Stock Gets Fair Value Boost After Q3 Analyst Revisions
Halozyme Therapeutics (HALO) Stock Looks In Line As ENHANZE Approval Lands
Can You Make Money Off Halozyme Stock Now?
Halozyme Therapeutics' Current Royalty Portfolio Expected to Peak in 2029, Morgan Stanley Says
Will HALO's Partner Royalties Drive Growth for the Rest of 2026?
Morgan Stanley Downgrades Halozyme Therapeutics to Equal-Weight, Raises Price Target to $109
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Halozyme Therapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation
Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?
HALO Q3 2026 deep dive: royalty expansion and next-gen platform investments drive outlook update
Leerink Partners Downgrades Halozyme Therapeutics to Market Perform, Raises Price Target to $117
Halozyme Therapeutics (HALO) Following Record Results And Higher Guidance Is The Stock Still Undervalued
Halozyme Stocks Slip 4.28% Despite 39% Revenue Growth and Modestly Higher Guidance
Halozyme Stock Down Despite Q3 Earnings and Revenue Beat
Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029
HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute
Halozyme Stock Jumps On Strong Earnings But Guidance Reset Raises Questions
Citizens Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $149
Halozyme Therapeutics Confirms It Anticipates $0 To Minimal Royalty Revenue Impact Based On Nov. 5 U.S. Centers For Medicare & Medicaid Services's Final Rule For Medicare Drug Price Negotiation Program
Evercore ISI Group Maintains Outperform on Halozyme Therapeutics, Raises Price Target to $125
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.